Latest Period
Q4 2025
Security Snapshot
RELMADA THERAPEUTICS, INC. - Common stock, $0.001 par value per share (RLMD) Institutional Ownership
CUSIP: 75955J402
13F Institutional Holders and Ownership History from Q4 2019 to Q1 2026
Institutions Reporting
77
Shares (Excl. Options)
50,901,642
Price
$4.83
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common stock, $0.001 par value per share
- Symbol
- RLMD on Nasdaq
- Shares outstanding
- 107,951,510
- Price per share
- $7.38
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 50,901,642
- Total reported value
- $245,749,015
- % of total 13F portfolios
- 0%
- Share change
- +32,232,730
- Value change
- +$155,594,501
- Number of holders
- 77
- Price from insider filings
- $7.38
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- RLMD - RELMADA THERAPEUTICS, INC. - Common stock, $0.001 par value per share is tracked under CUSIP 75955J402.
- 77 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 77 to 20 between Q4 2025 and Q1 2026.
- Reported value moved from $245,749,015 to $35,433,729.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 77 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 75955J402?
CUSIP 75955J402 identifies RLMD - RELMADA THERAPEUTICS, INC. - Common stock, $0.001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75955J402:
Significant Owners of RELMADA THERAPEUTICS, INC. - Common stock, $0.001 par value per share (RLMD) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 10% | $35,932,374 | 7,439,415 | JANUS HENDERSON GROUP PLC | 30 Jan 2026 | |||
| Squadron Capital Management LLC | 9.9% | 0% | $31,283,007 | +$17,330,352 | 7,395,510 | +124% | Squadron Master Fund LP | 31 Dec 2025 |
| Commodore Capital LP | 5.1% | $40,630,789 | 5,505,527 | Commodore Capital LP | 27 Apr 2026 | |||
| Adage Capital Management, L.P. | 5.8% | $18,062,100 | 4,270,000 | Adage Capital Management, L.P. | 31 Dec 2025 | |||
| Spruce Street Capital LP | 5.6% | $17,284,546 | 4,086,181 | Spruce Street Capital LP | 31 Dec 2025 | |||
| Ikarian Capital, LLC | 4.8% | $7,122,152 | 3,543,359 | Ikarian Capital, LLC | 30 Sep 2025 |
As of 31 Dec 2025, 77 institutional investors reported holding 50,901,642 shares of RELMADA THERAPEUTICS, INC. - Common stock, $0.001 par value per share (RLMD). This represents 47% of the company’s total 107,951,510 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of RELMADA THERAPEUTICS, INC. - Common stock, $0.001 par value per share (RLMD) together control 44% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 6.7% | 7,270,000 | 0.02% | $35,041,400 | |
| Squadron Capital Management LLC | 6.2% | 6,700,000 | 0% | 14% | $32,361,000 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4% | 4,270,000 | 0.03% | $20,624,100 | |
| Spruce Street Capital LP | 3.8% | 4,086,181 | 0% | 6.5% | $19,736,254 |
| MARSHALL WACE, LLP | 3% | 3,189,662 | +1072% | 0.01% | $15,406,068 |
| Ikarian Capital, LLC | 2.8% | 3,068,359 | +66% | 1.9% | $14,820,175 |
| ORBIMED ADVISORS LLC | 2.4% | 2,610,600 | 0.27% | $12,609,198 | |
| AMERIPRISE FINANCIAL INC | 1.8% | 1,920,099 | 0% | $9,274,078 | |
| Driehaus Capital Management LLC | 1.7% | 1,880,006 | +154% | 0.06% | $9,080,429 |
| MILLENNIUM MANAGEMENT LLC | 1.5% | 1,673,017 | 0.01% | $8,080,672 | |
| BRAIDWELL LP | 1.5% | 1,582,257 | 0.24% | $7,642,301 | |
| BlackRock, Inc. | 1.2% | 1,267,503 | +150% | 0% | $6,122,039 |
| VANGUARD GROUP INC | 1.1% | 1,203,307 | +187% | 0% | $5,811,973 |
| Opaleye Management Inc. | 0.87% | 935,000 | 0.6% | $4,516,050 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.79% | 854,932 | +189% | 0% | $4,131,406 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.77% | 835,300 | +20% | 0.11% | $4,034,499 |
| Corient Private Wealth LLC | 0.67% | 719,582 | +248% | 0% | $3,443,379 |
| TWO SIGMA INVESTMENTS, LP | 0.53% | 572,835 | +230% | 0% | $2,766,793 |
| Balyasny Asset Management L.P. | 0.51% | 547,854 | 0% | $2,646,135 | |
| ACADIAN ASSET MANAGEMENT LLC | 0.49% | 526,718 | -9.6% | 0% | $2,541,000 |
| DIADEMA PARTNERS LP | 0.36% | 389,395 | 1.1% | $1,880,778 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.36% | 385,942 | +179% | 0% | $1,864,100 |
| STATE STREET CORP | 0.3% | 320,820 | +215% | 0% | $1,549,561 |
| AdvisorShares Investments LLC | 0.3% | 319,510 | -21% | 0.26% | $1,543,233 |
| JANE STREET GROUP, LLC | 0.25% | 271,109 | +216% | 0% | $1,309,456 |
Institutional Holders of RELMADA THERAPEUTICS, INC. - Common stock, $0.001 par value per share (RLMD) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 5,091,065 | $35,433,729 | +$3,673,669 | $6.96 | 20 |
| 2025 Q4 | 50,901,642 | $245,749,015 | +$155,594,501 | $4.83 | 77 |
| 2025 Q3 | 7,739,580 | $15,541,689 | +$5,248,275 | $2.01 | 43 |
| 2025 Q2 | 5,303,151 | $3,177,608 | -$311,761 | $0.60 | 48 |
| 2025 Q1 | 6,219,491 | $1,678,348 | -$765,348 | $0.27 | 43 |
| 2024 Q4 | 8,399,225 | $4,362,564 | -$9,886,723 | $0.52 | 48 |
| 2024 Q3 | 12,376,687 | $40,240,571 | -$3,630,516 | $3.24 | 69 |
| 2024 Q2 | 13,555,167 | $40,671,232 | -$3,047,999 | $3.00 | 78 |
| 2024 Q1 | 14,295,630 | $66,487,069 | +$3,440,282 | $4.65 | 90 |
| 2023 Q4 | 13,621,440 | $56,386,775 | -$3,313,848 | $4.14 | 83 |
| 2023 Q3 | 14,992,668 | $44,979,292 | -$3,168,578 | $3.00 | 87 |
| 2023 Q2 | 16,099,667 | $39,628,526 | -$4,052,287 | $2.46 | 91 |
| 2023 Q1 | 17,764,331 | $40,142,172 | -$4,573,760 | $2.26 | 87 |
| 2022 Q4 | 19,144,470 | $66,816,077 | -$456,735,123 | $3.49 | 106 |
| 2022 Q3 | 25,783,847 | $954,470,507 | +$46,796,895 | $37.02 | 131 |
| 2022 Q2 | 24,632,853 | $467,785,642 | +$33,496,825 | $18.99 | 106 |
| 2022 Q1 | 23,069,358 | $622,305,579 | +$69,498,228 | $26.99 | 107 |
| 2021 Q4 | 20,739,885 | $467,189,248 | +$239,138,409 | $22.53 | 91 |
| 2021 Q3 | 10,023,314 | $262,675,920 | -$4,620,967 | $26.21 | 81 |
| 2021 Q2 | 9,944,006 | $318,306,821 | +$11,580,961 | $32.01 | 83 |
| 2021 Q1 | 9,536,264 | $335,739,251 | +$3,534,612 | $35.21 | 81 |
| 2020 Q4 | 9,311,019 | $298,677,225 | -$48,362,964 | $32.07 | 79 |
| 2020 Q3 | 10,443,239 | $392,874,164 | -$4,538,306 | $37.62 | 72 |
| 2020 Q2 | 10,506,228 | $469,323,200 | +$57,833,259 | $44.75 | 74 |
| 2020 Q1 | 9,357,083 | $319,169,853 | +$94,707,648 | $34.11 | 43 |
| 2019 Q4 | 6,797,480 | $265,100,975 | +$264,710,973 | $39.00 | 44 |